### Measuring Respiratory Symptoms of COPD: Performance of the EXACT- Respiratory Symptoms Tool (E-RS) in Three Clinical Trials

NK Leidy, PhD<sup>1§</sup>; LT Murray, MPH<sup>1</sup>; BU Monz, MD, MA, MPH<sup>2</sup>; L Nelsen, MHS<sup>3</sup>; M Goldman, MD<sup>4</sup>; PW Jones, PhD, FRCP<sup>5</sup>; EJ Dansie, PhD<sup>1</sup>; S Sethi, MD<sup>6</sup>

<sup>1</sup>Evidera, Bethesda, MD, US; <sup>2</sup>Formerly Boehringer Ingelheim GmbH, Ingelheim, Germany; <sup>3</sup>Merck, Sharp & Dohme, Corp, Whitehouse Station, NJ; <sup>4</sup>AstraZeneca, Wilmington, DE, US; <sup>5</sup>St. George's, University of London, London, UK; <sup>6</sup>University of Buffalo, Buffalo, NY, US

#### **ADDITIONAL FILE 1 - ONLINE SUPPLEMENT**

### **E-RS Score Reliability**

#### Data Source: Mpex

## Table E1- Seven-day Reproducibility of E-RS Daily Scores during Study Run-in Period\*(N=235)

E-RS Scores	$\mathbf{N}^{\dagger}$	Day -7 Mean (SD)	Day -1 Mean (SD)	Mean Difference <sup>‡</sup> (SD)	p Value <sup>‡</sup>	Effect Size <sup>§</sup>	ICC¶
RS-Total Score	168	15.7 (6.87)	16.4 (6.33)	-0.8 (4.98)	0.0508	-0.12	0.71
<b>RS-Breathlessness Score</b>	168	8.3 (3.93)	8.6 (3.77)	-0.4 (2.80)	0.1055	-0.09	0.73
RS-Cough and Sputum Score	168	4.2 (1.96)	4.3 (1.69)	0.0 (1.68)	0.7486	-0.02	0.58
<b>RS-Chest Symptoms Score</b>	168	3.2 (2.36)	3.5 (2.22)	-0.4 (1.79)	0.0093	-0.16	0.69

\*Pre-treatment, Cycle 1, Day -7; Day -1. Baseline scores represent the participant's stable or usual state.

<sup>†</sup>Number of study participants.

<sup>‡</sup>Mean difference = average Day -7 RS-score - average Day -1 RS score; p value from paired *t*-test.

<sup>§</sup>Effect size = Day -7 RS score - Day -1 RS score/SD of Day -1 RS score.

<sup>¶</sup>Intraclass correlation coefficient (ICC) based on random-effect model.

## Table E2- Reproducibility of E-RS Scores in Patients Reporting No Change\* for 2Consecutive Days before Treatment (Cycle 1, Day -2 and Day -1) (N=235)

E-RS Scores	$\mathbf{N}^{\dagger}$	Day -2 Mean (SD)	Day -1 Mean (SD)	Mean Difference <sup>‡</sup> (SD)	p Value <sup>‡</sup>	Effect Size <sup>§</sup>	ICC¶
RS-Total Score	170	15.0 (5.94)	15.3 (5.67)	-0.3 (2.44)	0.0755	-0.06	0.91
<b>RS-Breathlessness Score</b>	170	7.8 (3.52)	8.1 (3.32)	-0.3 (1.71)	0.0231	-0.09	0.87
RS-Cough and Sputum Score	170	4.0 (1.70)	4.0 (1.73)	0.0 (0.97)	0.8749	-0.01	0.84
RS-Chest Symptoms Score	170	3.2 (2.26)	3.2 (2.12)	0.0 (1.03)	0.7666	-0.01	0.89

\*Patients reporting "about the same" on item "Overall, how was your lung condition today compared to yesterday?"

<sup>†</sup>Number of study participants.

<sup>\*</sup>Mean difference = average Day -2 RS-score - average Day -1 RS score; p value from paired *t*-test. Where data are missing for one of those days, the most recent pair of consecutive days was used (i.e., Day -2 and Day -3).

<sup>§</sup>Effect size = Day -2 RS score - Day -1 RS score/SD of Day -1 RS score.

<sup>¶</sup>Intraclass correlation coefficient (ICC) based on random-effect model.

# Table E3- Reproducibility of E-RS Mean Weekly Scores from Cycle 1, Day -7 to Day -1 to<br/>Cycle 3, Day 22 to Day 28 in Unchanged Patients Identified Using the SGRQ\*<br/>(N=235)

E-RS Scores	$\mathbf{N}^{\dagger}$		Cycle 1, Day -7 to Day -1 Mean (SD)	Mean Difference <sup>‡</sup> (SD)	p Value <sup>‡</sup>	Effect Size <sup>§</sup>	ICC¶
RS-Total Score	63	15.5 (5.16)	15.8 (5.77)	-0.3 (4.26)	0.6160	-0.05	0.70
<b>RS-Breathlessness Score</b>	63	8.6 (3.18)	8.5 (3.40)	0.0 (2.30)	0.9173	0.01	0.76
RS-Cough and Sputum Score	63	4.0 (1.40)	4.1 (1.59)	-0.1 (1.45)	0.4640	-0.09	0.53
<b>RS-Chest Symptoms Score</b>	63	2.9 (1.97)	3.1 (2.08)	-0.2 (1.63)	0.4240	-0.08	0.68

\*For SGRQ total scores, 'unchanged' defined as a score change greater than -4.00 and less than 4 from baseline (Cycle 1, Day 1) to Cycle 4, Day 1.

<sup>†</sup>Number of study participants.

<sup>\*</sup>Mean difference = average Day -2 RS-score - average Day -1 RS score; p value from paired *t*-test.

<sup>§</sup>Effect size = Cycle 3, Day 22 to Day 28 RS score-Cycle 1, Day -7 to Day -1/SD of Cycle 1, Day -7 to Day -1 RS score.

<sup>¶</sup>Intraclass correlation coefficient (ICC) based on random-effect model.

Mean change (SD) for patients with no change in health status (SGRQ) from baseline to Day 28

was -0.3 (4.26) for the RS-Total and ranged from -0.2 (1.63) to 0.0 (2.30) for the domain scores.

Mean percent change for the RS-Total score was 4.1% with an ES of -0.05. Domain mean

percent changes ranged from 0.2% to 14.1% with ES ranging from -0.09 to 0.01.

### **E-RS Score Responders and Non-Responders**

Descriptive statistics for E-RS scores using the proposed responder definitions for symptomatic improvement are shown in Table E4.

						A (
	Ν	Baseline Mean (SD)	Week 12 Mean (SD)	Change Mean (SD)	Effect Size	% Change Mean (SD)
RS-Total (Range: 0-40)						
Responders ( $\geq$ -2 points)						
Mpex	84	17.6 (6.0)	12.4 (6.0)	-5.3 (3.0)	0.88	-33 (19)
AZ 1	284	17.6 (6.0)	11.5 (5.5)	-6.2 (4.1)	1.02	-36 (19)
AZ 2	255	20.0 (5.6)	13.0 (5.8)	-6.9 (4.4)	1.24	-36 (20)
Non-Responders (< -2 points	5)					
Mpex	137	14.4 (5.6)	16.3 (6.3)	1.9 (3.3)	0.34	16 (33)
AZ 1	438	14.8 (5.7)	16.8 (6.5)	2.0 (3.7)	0.35	18 (43)
AZ 2	322	16.8 (6.0)	18.5 (6.6)	1.7 (2.9)	0.28	12 (24)
RS-Breathlessness (Range:	0-17)					
Responders (≥-1 point)						
Mpex	72	8.3 (3.9)	5.4 (3.7)	-2.9 (1.7)	0.74	-43 (28)
AZ 1	266	8.6 (3.1)	5.5 (2.9)	-3.2 (2.0)	1.02	-39 (23)
AZ 2	244	9.5 (2.9)	6.2 (3.0)	-3.3 (2.2)	1.17	-36 (22)
Non-Responders (< -1 point)	)					
Mpex	149	8.1 (3.3)	9.3 (3.3)	1.2 (1.9)	0.37	21 (45)
AZ 1	456	7.5 (3.1)	8.7 (3.4)	1.1 (1.9)	0.36	23 (54)
AZ 2	333	8.5 (2.3)	9.5 (3.5)	1.0 (1.6)	0.30	16 (41)
RS-Cough and Sputum (Ra	nge: 0–	11)				
Responders (≥-0.7 point)						
Mpex	85	4.6 (1.3)	2.9 (1.3)	-1.7 (1.0)	1.39	-39 (22)
AZ 1	309	4.7 (1.5)	3.0 (1.4)	-1.8 (1.0)	1.18	-39 (21)
AZ 2	267	5.2 (1.6)	3.1 (1.6)	-2.1 (1.2)	1.31	-41 (23)
Non-Responders (< -0.7 poir	ıt)					
Mpex	136	3.8 (1.7)	4.4 (1.6)	0.5 (1.1)	0.31	30 (79)
AZ 1	413	3.8 (1.5)	4.2 (1.6)	0.4 (1.0)	0.29	16 (42)
AZ 2	310	4.3 (1.5)	4.6 (1.7)	0.4 (0.8)	0.25	12 (30)
<b>RS-Chest Symptoms (Rang</b>	e: 0–12)	)				
Responders ( $\geq$ -0.7 point)						
Mpex	78	4.1 (2.0)	2.1 (1.9)	-2.0 (1.1)	1.00	-58 (29)
AZ 1	270	4.5 (1.8)	2.5 (1.7)	-2.0 (1.3)	1.08	-48 (26)
AZ 2	240	5.2 (1.7)	3.1 (1.7)	-2.2 (1.3)	1.30	-43 (24)
Non-Responders (< -0.7 poir	ıt)					
Mpex	143	2.9 (2.0)	3.5 (2.2)	0.6 (1.1)	0.28	27 (95)
AZ 1	452	3.4 (1.9)	4.1 (2.2)	0.7 (1.2)	0.39	43 (175)
AZ 2	337	4.2 (2.0)	4.8 (2.2)	0.6 (1.0)	0.31	19 (44)

 Table E4
 - Change in E-RS Scores Baseline to Week 12 by Responder Status<sup>\*</sup> and Trial

\*Responder: Symptomatic improvement; Non-Responder: No change or worsening.

Weekly mean changes in E-RS symptom scores over 12 weeks by responder status are shown in

Figures E1a–E1d.




Figure E1a - Mean (SE) Change in RS-Total Scores Over 12 Weeks by Responder Status\* and Trial

Figure E1b - Mean (SE) Change in RS-Breathlessness Scores Over 12 Weeks by Trial




Figure E1c - Mean (SE) Change in RS-Cough and Sputum Scores Over 12 Weeks by Trial





Figure E1d - Mean (SE) Change in RS-Chest Symptoms Scores Over 12 Weeks by Trial



<sup>\*</sup>Responder: Symptomatic improvement; Non-Responder: No change or worsening. Higher E-RS Scores: More severe symptoms; Negative Change Scores: Symptomatic improvement

### E-RS Scores for Non-Responders with Indications of Worsening

Exploratory analyses were performed to examine E-RS score changes in subjects experiencing deterioration in health status (SGRQ  $\geq$ 4 points) or on an alternative measure of symptoms (BCSS  $\geq$ 1 point) over 12 weeks. Student's *t*-test, percent change, and ES were used to evaluate the magnitude of E-RS score change from baseline. Results are shown in Table E5.

Criterion Trial (n) Parameter	<b>RS-Total</b>	<b>RS-Breathlessness</b>	RS-Cough and Sputum	RS-Chest Symptoms
SGRQ ≥ 4.0				
Mpex (n=39)				
Mean (SD)	2.0 (4.61)**	1.4 (2.28)***	0.10 (1.58)	0.50 (1.66)
% Change	19	24	14	18
Effect Size	0.38	0.3	0.09	0.21
AZ 1 (n=185)				
Mean (SD)	0.9 (5.9)*	0.5 (2.9)*	0.0 (1.7)	0.4 (1.9)**
% Change	10	12	8	29
Effect Size	0.16	0.16	0.02	0.22
AZ 2 (n=124)				
Mean (SD)	-0.4 (5.9)	0.0 (2.8)	-0.3 (1.5)**	-0.1 (1.7)
% Change	2	6	5	3
Effect Size	0.07	0.01	0.21	0.03
BCSS ≥ 1.0				
AZ 1 (n=241)				
Mean (SD)	3.4 (4.4)****	1.5 (2.4)****	0.8 (1.2)****	1.0 (1.6)****
% Change	31	31	30	68
Effect Size	0.56	0.49	0.54	0.54
AZ 2 (n=61)				
Mean (SD)	5.1 (3.4)*	2.2 (2.2)*	1.4 (1.0)*	1.5 (1.4)*
% Change	34	33	40	47
Effect Size	0.89	0.73	1.01	0.70

Table E5         - E-RS Change Score Parameters for Subjects Reporting Worsening	Condition
Baseline <sup>+</sup> to Week 12	

<sup>†</sup>Deterioration in health status (SGRQ) or symptoms (BCSS).

\*p<0.05; \*\*p<0.01; \*\*\*p<0.001; \*\*\*\*p<0.0001.

To evaluate the possibility of symmetric thresholds (same absolute value applied to improvement and worsening), the following threshold values were used to identify patients with symptomatic deterioration ( $\geq 2.0$ ,  $\geq 1.0$ ,  $\geq 0.70$ , and  $\geq 0.70$  for the total and 3 subscales, respectively). Table E6 shows the mean and percentage change in E-RS score and ES estimates for these patients.

E-RS Scale Trial	N	Baseline Mean (SD)	Week 12 Mean (SD)	Change Mean (SD)	Effect Size	% Change Mean (SD)
RS-Total (Range: 0-40)	)	_				_
Symptomatic Decline (2	<u>2.0 points</u> )					
Mpex	55	13.8 (4.82)	18.8 (5.59)	4.9 (3.15)	1.02	42.0 (36.98)
AZ 1	158	14.7 (5.87)	20.3 (6.54)	5.6 (3.96)	0.96	49.9 (58.13)
AZ 2	118	16.2 (5.79)	20.9 (6.30)	4.7 (2.58)	0.81	34.5 (25.48)
<b>RS-Breathlessness (Ran</b>	nge: 0–17)					
Worse Breathlessness (2	<u>2</u> 1.0 points)					
Mpex	61	7.5 (2.96)	10.5 (2.71)	2.9 (1.81)	1.00	53.6 (53.26)
AZ 1	192	7.3 (3.01)	10.0 (3.29)	2.7 (1.88)	0.90	51.9 (71.47)
AZ 2	137	8.1 (3.12)	10.6 (3.34)	2.5 (1.48)	0.79	41.0 (49.80)
<b>RS-Cough and Sputum</b>	(Range: 0-11	)				
Worse Cough & Sputun	n (≥ 0.7 points)					
Mpex	42	3.0 (1.62)	4.8 (1.68)	1.8 (1.02)	1.14	97.8 (114.9)
AZ 1	114	3.5 (1.47)	5.2 (1.71)	1.7 (1.12)	1.14	59.3 (56.71)
AZ 2	90	4.0 (1.35)	5.5 (1.49)	1.4 (0.68)	1.08	41.9 (34.30)
<b>RS-Chest Symptoms (R</b>	lange: 0–12)					
Worse Chest Symptoms	$(\geq 0.7 \text{ points})$					
Mpex	46	2.5 (1.70)	4.4 (1.94)	1.8 (1.03)	1.08	103.4 (130.9)
AZ 1	173	3.3 (1.87)	5.2 (2.16)	1.9 (1.21)	1.03	121.1 (262.9)
AZ 2	126	4.0 (1.88)	5.7 (2.07)	1.7 (0.90)	0.89	55.4 (49.63)

 Table E6
 E-RS Change Scores Baseline to Week 12 for Subjects Exhibiting Symptomatic Decline\*

\*Using E-RS threshold estimates for decline

These results suggest the E-RS score thresholds for deterioration may be smaller than those used to identify treatment responders showing symptomatic improvement. Further study of the relationship between symptomatic deterioration of various magnitudes and other clinical outcomes, including exacerbations and mortality, over longer study periods is warranted.

Scale	Item-level Construct <sup>1</sup>	Item Number
<b>RS-Breathlessness</b>		
	Breathless today <sup>2</sup>	7
	Breathless with activity <sup>3</sup>	8
	Short of breath - personal care <sup>3</sup>	9
	Short of breath - indoor activity <sup>3</sup>	10
	Short of breath - outdoor activity <sup>3</sup>	11
RS-Cough and Sputum		
	Cough frequency <sup>3</sup>	2
	Mucus quantity <sup>3</sup>	3
	Difficulty with mucus <sup>2</sup>	4
RS-Chest Symptoms		
	Congestion <sup>2</sup>	1
	Discomfort <sup>2</sup>	5
	Tightness <sup>2</sup>	6
Respiratory Symptoms	E-RS Total	11 items
Additional Attributes		
Used in the EXACT total score for	Tired or weak <sup>2</sup>	12
characterizing exacerbations,	Sleep disturbance <sup>2</sup>	13
specifically.	Scared or worried <sup>2</sup>	14
EXACT – Exacerbations	EXACT Total Score	14 items

### Table E7 - Content and Structure of the EXACT and EXACT-RS<sup>a</sup>

<sup>a</sup> All 14 items of the EXACT are administered as a daily diary; E-RS scoring uses only the respiratory symptom items, with scoring based on summation to yield ordinal-level scales.
 <sup>1</sup> Items are worded as simple questions. Recall: "Today". Patients are asked to complete the diary every evening before they go

to bed, reflecting on their symptoms that day. The formatted instrument is available through exactpro@evidera.com.

<sup>2.</sup> 5-point scale, Not at all to Extremely

<sup>3.</sup> 5-point scale – other